Midterm results of a prospective randomized comparison of two different rabbit-antithymocyte globulin induction therapies after heart transplantation

Transplantation Proceedings

Volumn 36, Issue 3, 2004, Pages 631-637

  De Santo, L S ^a,b   Della Corte, A ^a   Romano, G ^a   Amarelli, C ^a   Onorati, F ^a   Torella, M ^a   De Feo, M ^a   Marra, C ^a   Maiello, C ^a   Giannolo, B ^a   Casillo, R ^a   Ragone, E ^a   Grimaldi, M ^a   Utili, R ^a   Cotrufo, M ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b NONE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOSUPPRESSIVE AGENT; POLYCLONAL ANTIBODY; RABBIT ANTISERUM; STEROID; THYMOCYTE ANTIBODY;

ACUTE GRAFT REJECTION; ADOLESCENT; ADULT; ATHEROSCLEROSIS; CARCINOMA; CLINICAL ARTICLE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOMEGALOVIRUS; DEMOGRAPHY; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; FOLLOW UP; HEART TRANSPLANTATION; HUMAN; HUMAN TISSUE; IMMUNOLOGY; INCIDENCE; INFECTION; MALE; POSTOPERATIVE COMPLICATION; POSTOPERATIVE PERIOD; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RECIPIENT; SURVIVAL RATE; TREATMENT OUTCOME; VIRUS REACTIVATION;

ADULT; ANIMALS; ANTILYMPHOCYTE SERUM; BLOOD CHEMICAL ANALYSIS; CAUSE OF DEATH; CHEMISTRY, PHARMACEUTICAL; FEMALE; GRAFT REJECTION; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LEUKOCYTE COUNT; MALE; RABBITS; SURVIVAL ANALYSIS;

EID: 11144357187     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2004.02.053     Document Type: Conference Paper

References (30)

1. Hosenpud J.D., Bennet L.E., Keck B.M. The Registry of the International Society for Heart and Lung Transplantation seventeenth official report - 2000. J Heart Lung Transplant. 19:2000;909
2. Joun R., Rajasinghe H.A., Chen J.M., et al. Long-term outcomes after cardiac transplantation an experience based on different eras of immunosuppressive therapy. Ann Thorac Surg. 72:2001;440
3. Spratt P., Esmore D., Baron D., et al. Effects of low-dose cyclosporin A on toxicity and rejection in cardiac transplantation. Transplant Proc. 19:1987;2847
4. Carrier M., Jenicek M., Pelletier L.C. Value of monoclonal antibody OKT3 in solid organ transplantation a meta-analysis. Transplant Proc. 24:1992;2586
5. Carrier M., White M., Perrault L.P., et al. A 10-year experience with intravenous thymoglobuline in induction of immunosuppression following heart transplantation. J Heart Lung Transplant. 18:1999;1218
6. Bonnefoy-Berard N., Revillard J.P. Mechanisms of immunosuppression induced by antithymocyte globulins and OKT3. J Heart Lung Transplant. 15:1996;435
7. Genestier L., Fournel S., Flacher M., et al. Induction of Fas(Apo-1, CD95)-mediated apoptosis of activated lymphocytes by policlonal antithymocyte globulins. Blood. 91:1998;2360
8. Beaufigeau M., Dumesnil D., Carrier M., et al. Seven-year experience with rabbit antithymocyte globulin after cardiac transplantation at the Montreal Heart Institute. Transplant Proc. 29:1997;10S
9. Lavee J., Bar-Zohar D., Har-Zahav Y., et al. Immunosuppression induction with rabbit antithymocyte globulin in heart transplantation patients 6-year experience at the Sheba Medical Center. Transplant Proc. 32:2000;737
10. Chien N.C., Lin F.L., Chou N.K., et al. Rabbit antithymocyte globulin induction immunosuppression in heart transplantation. Transplant Proc. 32:2000;2380
11. Lower R.R., Shumway N.E. Studies on the orthotopic homotransplantations of the canine heart. Surg Forum. 11:1960;18
12. Billingham M.E., Cary N.R.B., Hammond M.E., et al. A working formulation for the standardization of nomenclature in the diagnosis of heart and lung rejection heart rejection study group. J Heart Transplant. 9:1990;587
13. Kormos R.L., Herlan D.B., Armitage J.M., et al. Monoclonal versus polyclonal antibody therapy for prophylaxis against rejection after heart transplantation. J Heart Transplant. 9:1990;1
14. Renlund D.G., O'Connell J.B., Gilbert E.M., et al. A prospective comparison of murine monoclonal CD-3 (OKT3) antibody-based and equine antithymocyte globulin-based rejection prophylaxis in cardiac transplantation. Decreased rejection and less corticosteroid use with OKT3. Transplantation. 47:1989;599
15. Swinnen L.J., Costanzo-Nordin M.R., Fisher S.G., et al. Increased incidence of lymphoproliferative disorders after immunosuppression with the monoclonal antibody OKT3 in cardiac-transplant recipients. N Engl J Med. 323:1990;1723
16. Mcdonalnd P.S., Mundy J., Keogh A.M., et al. A prospective randomised study of prophylactic OKT3 versus equine antithymocyte globulin after heart transplantation. Increased morbidity with OKT3. Transplantation. 55:1993;110
17. Bourdage J.S., Hamlin D.M. Comparative polyclonal antithymocyte globulin and antilymphocyte/antilymphoblast globulin anti-CD antigen analysis by flow cytometry. Transplantation. 59:1995;1194
18. Krogsgaard K., Boesgaard S., Aldershvile J., et al. Cytomegalovirus infection rate among heart transplant patients in relation to anti-thymocyte immunoglobulin induction therapy. Scand J Infect Dis. 26:1994;239
19. Leger PH, Pavie A: Comparison de deux globulines antithymocytaires, Fresenius et Merieux, en tranplantation cardiaque. In Cabrol C, Gandjbakhch I, Pavie A (eds): Les Journees Hospital de la Pitie. Paris: 1994. 1995, p 103
20. Zuckermann A.O., Grimm M., Czerny M., et al. Improved long-term results with thymoglobuline induction therapy after cardiac transplantation; a comparison of two different rabbit-antithymocyte globulines. Transplantation. 69:2000;1890
21. Müller T.F. Long-term T cell dynamics following the use of polyclonal and monoclonal antibodies. Graft. 21:1999;15
22. Balk A.H., Weimar W., Rothbarth P.H., et al. Passive immunization against cytomegalovirus in allograft recipients. The Rotterdam heart transplant program experience. Infection. 21:1993;195
23. Gamadia LE, Remmerswaal EB, Weel JF, et al. Primary immune responses to human cytomegalovirus: a critical role for IFN-gamma-producing CD4+ T cells in protection against CMV-disease. Blood 101:2686, 2003
24. Sester M., Sester U., Gartner B.C., et al. Dominance of virus-specific CD8 T cells in human primary cytomegalovirus infection. J Am Soc Nephrol. 13:2002;2577
25. Essa S., Pacsa A.S., Raghupathy R., et al. CD4(+) T cell levels are decreased during active CMV infection in kidney transplant recipients. FEMS Immunol Med Microbiol. 34:2002;17
26. John R., Rajasinghe H., Chen J.M., et al. Impact of current management practices on early and late death in more than 500 consecutive cardiac transplant recipients. Ann Surg. 232:2000;302
27. McGiffin D.C., Kirklin J.K., Naftel D.C., et al. Competing outcomes after heart transplantation a comparison of eras and outcomes. J Heart Lung Transplant. 16:1997;190
28. Gao S.Z., Schroeder J.S., Aldermann E.L., et al. Prevalence of accelerated coronary artery disease in heart transplant survivors comparison of cyclosporine and azathioprine regimens. Circulation. 80:1989;S100
29. Koskinen P.K., Nieminen M.S., Krogerus L.A., et al. Cytomegalovirus infection accelerates cardiac allograft vasculopathy correlation between angiographic and endomyocardial biopsy findings in heart transplant recipients. Transplant Int. 6:1993;341
30. Zerbe T., Uretsky B., Kormos R., et al. Graft atherosclerosis effects of cellular rejection and human lymphocyte antigen. J Heart Lung Transplant. 11:1992;S104